Feedback
Settings

Settings

Goto Application

1. WO2022093742 - COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES

Submit observation
PermaLink
Publication Number WO/2022/093742
Publication Date 05.05.2022
International Application No. PCT/US2021/056545
International Filing Date 26.10.2021
IPC
A61K 31/4035 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
4035Isoindoles, e.g. phthalimide
A61K 31/435 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/4525 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
4525containing a five-membered ring with oxygen as a ring hetero atom
C07D 401/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
C07D 401/14 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
C07D 471/04 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Applicants
  • DANA-FARBER CANCER INSTITUTE, INC. [US]/[US]
  • KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KIST) [KR]/[KR]
  • GRAY, Nathanael S. [US]/[US]
  • FISCHER, Eric S. [DE]/[US]
  • FERGUSON, Fleur M. [GB]/[US]
  • DONOVAN, Katherine [NZ]/[US]
  • BUSHMAN, Jonathan W. [US]/[US]
  • SIM, Taebo [KR]/[KR]
  • BHUNIA, Debabrata [IN]/[IN]
  • RYU, SeongShick [KR]/[KR]
Inventors
  • GRAY, Nathanael S.
  • FISCHER, Eric S.
  • FERGUSON, Fleur M.
  • DONOVAN, Katherine
  • BUSHMAN, Jonathan W.
  • SIM, Taebo
  • BHUNIA, Debabrata
  • RYU, SeongShick
Agents
  • CLARKE, Daniel W.
  • BUCHANAN, John
  • CARROLL, Christopher
  • JOSEPH, Ricardo
  • COHEN, Jerry
  • FOLEY, Shawn
  • KARIMI, Pegah
  • LORENC, Chris
  • MARAIA, Joseph M.
  • MCGRATH, Daniel
  • MILLS, Steven M.
  • PYSHER, Paul
  • QUINN, Joseph P.
  • SCHEPPER GROLNIC, Marlo
  • SCHULTZ, Christopher
  • SUSAN, Janine M.
  • JOBSE, Bruce D.
Priority Data
63/105,72826.10.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES
(FR) COMPOSÉS POUR LA DÉGRADATION CIBLÉE DE PROTÉINES DE KINASES
front page image
Abstract
(EN) The present invention relates to bifunctional compounds for targeted kinase degradation, methods for treating diseases or conditions mediated by aberrant kinase activity, and methods for identifying degradable kinases and optimal kinase: scaffold pairs.
(FR) La présente invention concerne des composés bifonctionnels pour la dégradation ciblée de kinases, des méthodes pour le traitement de maladies ou d'affections à médiation par une activité de kinase aberrante, et des méthodes pour l'identification de kinases dégradables et de paires d'échafaudage de kinases optimales.
Latest bibliographic data on file with the International Bureau
# -